A tumor biomarker analysis of ASPS affirms the presence of PD-1/PD-L1 immune checkpoint components, suggesting that immune checkpoint inhibition could be beneficial in advanced ASPS [40]. The gene discussed is CD274; the disease is alveolar soft part sarcoma.